CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for codeine phosphate; promethazine hydrochloride and what is the scope of patent protection?
Codeine phosphate; promethazine hydrochloride
is the generic ingredient in five branded drugs marketed by Ani Pharms, Halsey, Actavis Mid Atlantic, Amneal Pharms, Hikma, Nostrum Labs Inc, Pharm Assoc, Quagen, Tris Pharma Inc, Wockhardt Bio Ag, and Cenci, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.Six suppliers are listed for this compound.
Summary for CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
| US Patents: | 0 |
| Tradenames: | 5 |
| Applicants: | 11 |
| NDAs: | 12 |
| Finished Product Suppliers / Packagers: | 6 |
| DailyMed Link: | CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE at DailyMed |
Pharmacology for CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
| Drug Class | Opioid Agonist Phenothiazine |
| Mechanism of Action | Full Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
US Patents and Regulatory Information for CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cenci | PROMETHAZINE W/ CODEINE | codeine phosphate; promethazine hydrochloride | SYRUP;ORAL | 088814-001 | Nov 22, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Amneal Pharms | PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE | codeine phosphate; promethazine hydrochloride | SYRUP;ORAL | 200894-001 | Apr 24, 2013 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Tris Pharma Inc | PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE | codeine phosphate; promethazine hydrochloride | SYRUP;ORAL | 200386-001 | Jun 29, 2012 | AA | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
